

Patterns of Diagnosis and Acute and Preventive Treatment States: Results from the American Migraine Prevalence

Headache

47, 061117080657014-???

DOI: 10.1111/j.1526-4610.2006.00631.x

Citation Report

#	ARTICLE	IF	CITATIONS
1	Resource use associated with topiramate in migraine prophylaxis. American Journal of Health-System Pharmacy, 2007, 64, 1483-1491.	0.5	10
2	Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 2007, 68, 343-349.	1.5	1,943
3	The cycle of migraine: Patients' quality of life during and between migraine attacks. Clinical Therapeutics, 2007, 29, 939-949.	1.1	79
4	Concomitant Triptan and SSRI or SNRI Use: A Risk for Serotonin Syndrome. Headache, 2007, 48, 071115145930001-???.	1.8	20
5	Epidemiology and diagnosis of migraine in children. Current Pain and Headache Reports, 2007, 11, 375-382.	1.3	34
6	Classification of pediatric headache. Current Pain and Headache Reports, 2008, 12, 357-360.	1.3	15
7	Psychological issues in the evaluation and treatment of tension-type headache. Current Pain and Headache Reports, 2008, 12, 425-432.	1.3	3
8	The Migraine Cycle: Patient Burden of Migraine During and Between Migraine Attacks. Headache, 2008, 48, 430-441.	1.8	65
9	A Migraine Prophylaxis Educational Intervention in a Medicaid Population. Headache, 2008, 48, 267-271.	1.8	6
10	Responsiveness of Migraine ACT and MIDAS Questionnaires for Assessing Migraine Therapy. Headache, 2008, 48, 1349-1355.	1.8	15
11	The Headache Management Trial: A Randomized Study of Coordinated Care. Headache, 2008, 48, 1294-1310.	1.8	57
12	A Pivotal Moment in 50 Years of Headache History: The First American Migraine Study. Headache, 2008, 48, 730-731.	1.8	20
13	Toward an Epidemiology of Refractory Migraine: Current Knowledge and Issues for Future Research. Headache, 2008, 48, 791-798.	1.8	20
14	Analysis of Headache Management in a Busy Emergency Room in the United States. Headache, 2008, 48, 931-938.	1.8	44
15	Assessing Functional Impairment During and Between Migraine Attacks. Journal for Nurse Practitioners, 2008, 4, 201-207.	0.4	3
16	Migraine Associated Cerebral Hyperperfusion with Arterial Spin-Labeled MR Imaging. American Journal of Neuroradiology, 2008, 29, 1494-1497.	1.2	74
17	Survey to evaluate diagnosis and management of headache in primary care: Headache Management Pattern programme. Current Medical Research and Opinion, 2008, 24, 3413-3422.	0.9	15
18	The management of the patient with acromegaly and headache: A still open clinical challenge. Journal of Endocrinological Investigation, 2008, 31, 919-924.	1.8	17

#	ARTICLE	IF	CITATIONS
19	Serotonin Syndrome Risks When Combining SSRI/SNRI Drugs and Triptans: is the FDA's Alert Warranted?. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1692-1696.	0.9	30
20	Treating migraine in the emergency department. <i>BMJ: British Medical Journal</i> , 2008, 336, 1320-1320.	2.4	4
21	Impact of comorbidity on headache-related disability. <i>Neurology</i> , 2008, 70, 538-547.	1.5	133
22	Chronic migraine in the population. <i>Neurology</i> , 2008, 71, 559-566.	1.5	434
23	How long should patients with migraine continue to receive prophylactic topiramate?. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 294-295.	2.7	3
24	Prevalence and characteristics of allodynia in headache sufferers. <i>Neurology</i> , 2008, 70, 1525-1533.	1.5	320
25	Easing the pain: challenges and opportunities in headache management. <i>British Journal of General Practice</i> , 2008, 58, 77-78.	0.7	11
26	Migraine-preventive medications: Ensuring their appropriate use. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2008, 48, e107-e124.	0.7	4
27	Current migraine management – patient acceptability and future approaches. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1043.	1.0	21
28	Prophylaxis of migraine: general principles and patient acceptance. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1155.	1.0	80
29	Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations. <i>Patient Preference and Adherence</i> , 2009, 3, 161.	0.8	18
30	Chronic headache in the elderly. <i>Aging Health</i> , 2009, 5, 103-112.	0.3	0
31	Topiramate for Use in Adult Migraine Prophylaxis. <i>Journal of Pharmacy Technology</i> , 2009, 25, 100-110.	0.5	0
32	GERD prevalence in migraine patients and the implication for acute migraine treatment. <i>Journal of Headache and Pain</i> , 2009, 10, 35-43.	2.5	24
33	Is there an inherent limit to acute migraine treatment efficacy?. <i>Journal of Headache and Pain</i> , 2009, 10, 393-394.	2.5	5
34	Migraine prophylaxis: key points for the practising clinician. <i>Neurological Sciences</i> , 2009, 30, 33-37.	0.9	10
35	Underdiagnosis of primary headaches: results of a survey on patients attending headache centres. <i>Neurological Sciences</i> , 2009, 30, 129-131.	0.9	4
36	Overuse of acute migraine medications and migraine chronification. <i>Current Pain and Headache Reports</i> , 2009, 13, 301-307.	1.3	109

#	ARTICLE	IF	CITATIONS
37	The design and protocol of acupuncture for migraine prophylaxis: A multicenter randomized controlled trial. <i>Trials</i> , 2009, 10, 25.	0.7	10
38	Prevalence and Burden of Headache and Migraine in Germany. <i>Headache</i> , 2009, 49, 79-89.	1.8	133
39	Divalproex Sodium Extendedâ€Release for the Prophylaxis of Migraine Headache in Adolescents: Results of a Standâ€Alone, Longâ€Term Openâ€Label Safety Study. <i>Headache</i> , 2009, 49, 45-53.	1.8	32
40	Use of the Emergency Department for Severe Headache. A Populationâ€Based Study. <i>Headache</i> , 2009, 49, 21-30.	1.8	89
41	Development and Construct Validation of the Pharmacists' Care of Migraineurs Scale. <i>Headache</i> , 2009, 49, 54-63.	1.8	10
42	Safety and Tolerability of Divalproex Sodium Extendedâ€Release in the Prophylaxis of Migraine Headaches: Results of an Openâ€Label Extension Trial in Adolescents. <i>Headache</i> , 2009, 49, 36-44.	1.8	18
43	Evaluation of Carisbamate for the Treatment of Migraine in a Randomized, Doubleâ€Blind Trial. <i>Headache</i> , 2009, 49, 216-226.	1.8	32
44	Predictors of Adherence to Triptans: Factors of Sustained vs Lapsed Users. <i>Headache</i> , 2009, 49, 386-394.	1.8	31
45	Impact of Recent Prior Opioid Use on Rizatriptan Efficacy. A Post Hoc Pooled Analysis. <i>Headache</i> , 2009, 49, 395-403.	1.8	49
46	Barriers to Satisfactory Migraine Outcomes. What Have We Learned, Where Do We Stand?. <i>Headache</i> , 2009, 49, 1028-1041.	1.8	39
47	The Burden of Migraine in the United States: Current and Emerging Perspectives on Disease Management and Economic Analysis. <i>Value in Health</i> , 2009, 12, 55-64.	0.1	134
48	The Acute Treatment of Episodic and Chronic Migraine in the USA. <i>Cephalalgia</i> , 2009, 29, 891-897.	1.8	79
49	Underdiagnosis and Undertreatment of Migraine in Italy: A Survey of Patients Attending for The First Time 10 Headache Centres. <i>Cephalalgia</i> , 2009, 29, 1285-1293.	1.8	103
50	The Epidemiology, Burden, and Comorbidities of Migraine. <i>Neurologic Clinics</i> , 2009, 27, 321-334.	0.8	253
51	Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2009, 23, 396-408.	0.5	12
52	Migraine: A Question and Answer Review. <i>Medical Clinics of North America</i> , 2009, 93, 245-262.	1.1	8
56	Didactic Migraine Education in US Doctor of Pharmacy Programs. <i>American Journal of Pharmaceutical Education</i> , 2010, 74, 4.	0.7	5
58	Rizatriptan for acute migraine headaches in adults. , 2010, , .		2

#	ARTICLE	IF	CITATIONS
59	Aspirin with or without an antiemetic for acute migraine headaches in adults. , 2010, , CD008041.		36
61	Zolmitriptan for acute migraine headaches in adults. , 2010, , .		0
62	Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. Journal of Pharmacy and Pharmacology, 2010, 61, 1219-1228.	1.2	42
63	Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting. Journal of Headache and Pain, 2010, 11, 33-44.	2.5	13
64	Treatment of migraine and tension-type headache in Croatia. Journal of Headache and Pain, 2010, 11, 227-234.	2.5	9
65	Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. Journal of Headache and Pain, 2010, 11, 417-425.	2.5	90
66	Chronic headaches and medication overuse. Internal and Emergency Medicine, 2010, 5, 7-11.	1.0	45
67	Diagnosing migraine in research and clinical settings: The validation of the Structured Migraine Interview (SMI). BMC Neurology, 2010, 10, 7.	0.8	30
68	The Use of Migraine Preventive Medications Among Patients with and without Migraine Headaches. Cephalalgia, 2010, 30, 97-104.	1.8	35
69	Adherence to Acute Migraine Medication: What Does It Mean, Why Does It Matter?. Headache, 2010, 50, 117-129.	1.8	36
70	Triptan Use as a Function of Cardiovascular Risk. A Population-Based Study. Headache, 2010, 50, 256-263.	1.8	24
71	Expert Opinion: Rescue Me: Rescue Medication for Migraine. Headache, 2010, 50, 307-313.	1.8	9
72	Migraine Education Improves Quality of Life in a Primary Care Setting. Headache, 2010, 50, 600-612.	1.8	57
73	A Randomized, Placebo-Controlled Trial of Acetaminophen for Treatment of Migraine Headache. Headache, 2010, 50, 819-833.	1.8	43
74	Correlations between alexithymia and pain severity, depression, and anxiety among patients with chronic and episodic migraine. Psychiatry and Clinical Neurosciences, 2010, 64, 231-238.	1.0	34
75	Primary headaches in childhood – A population-based study. Cephalalgia, 2010, 30, 1056-1064.	1.8	74
76	Increased Risk of Pre-Eclampsia (PE) Among Women with the History of Migraine. Clinical and Experimental Hypertension, 2010, 32, 159-165.	0.5	23
77	Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 428-432.	0.9	481

#	ARTICLE	IF	CITATIONS
78	Therapeutic guidelines for headache. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 183-194.	1.0	1
79	Migraine and cardiovascular disease. Neurology, 2010, 74, 628-635.	1.5	290
80	The role of prevention. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 195-205.	1.0	4
81	Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting. Current Medical Research and Opinion, 2010, 26, 1119-1129.	0.9	8
82	Ibuprofen with or without an antiemetic for acute migraine headaches in adults. , 2010, , CD008039.		26
83	Sumatriptan plus naproxen for acute migraine headaches in adults. , 2010, 2010, .		2
84	OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine. Expert Opinion on Biological Therapy, 2010, 10, 289-298.	1.4	9
85	Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. , 2010, , CD008040.		21
86	Prescription patterns in preventive and abortive migraine medication. Cephalalgia, 2011, 31, 1659-1663.	1.8	11
87	Pathophysiology of medication overuse headache: Insights and hypotheses from preclinical studies. Cephalalgia, 2011, 31, 851-860.	1.8	51
89	Prophylaxis and Treatment of Menstrual Migraine. Pain Management Nursing, 2011, 12, S11-S16.	0.4	0
90	Migraine and cardiovascular disease. Arquivos De Neuro-Psiquiatria, 2011, 69, 122-129.	0.3	23
91	A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns. Neuropsychiatric Disease and Treatment, 2011, 7, 663.	1.0	22
92	Assessing the Impact of Migraine Onset on Work Productivity. Journal of Occupational and Environmental Medicine, 2011, 53, 74-81.	0.9	34
93	Longitudinal Change in Migraine Headache-Days and Indirect Cost Consequences. Journal of Occupational and Environmental Medicine, 2011, 53, 478-487.	0.9	11
96	Time Delay From Onset to Diagnosis of Migraine. Headache, 2011, 51, 232-236.	1.8	21
97	MAPO004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine. Headache, 2011, 51, 507-517.	1.8	84
98	Prevalence and Burden of Chronic Migraine in Adolescents: Results of the Chronic Daily Headache in Adolescents Study (Câ€dAS). Headache, 2011, 51, 693-706.	1.8	130

#	ARTICLE	IF	CITATIONS
99	Sex-Related Differences in Epidemiological and Clinic-Based Headache Studies. <i>Headache</i> , 2011, 51, 843-859.	1.8	81
100	Migraine and the Presidency. <i>Headache</i> , 2011, 51, 1431-1439.	1.8	2
101	Migraine Headaches: Diagnosis and Management. <i>Journal of Midwifery and Women's Health</i> , 2011, 56, 282-292.	0.7	5
102	Evaluation of the Migraine Treatment Sumatriptan/Naproxen Sodium on Blood Pressure Following Long-Term Administration. <i>Journal of Clinical Hypertension</i> , 2011, 13, 910-916.	1.0	6
103	Undertreatment in patients with primary headaches attending headache centres. <i>Neurological Sciences</i> , 2011, 32, 181-183.	0.9	22
104	Nonpharmacologic Treatments for Migraine and Tension-Type Headache: How to Choose and When to Use. <i>Current Treatment Options in Neurology</i> , 2011, 13, 28-40.	0.7	76
105	Symptomatic Treatment of Migraine: When to Use NSAIDs, Triptans, or Opiates. <i>Current Treatment Options in Neurology</i> , 2011, 13, 15-27.	0.7	21
106	Update on Medication-overuse Headache. <i>Current Pain and Headache Reports</i> , 2011, 15, 79-83.	1.3	43
107	Characteristics, impact and treatment of 6000 headache attacks: The PAMINA study. <i>European Journal of Pain</i> , 2011, 15, 205-212.	1.4	9
108	Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. <i>Neurology</i> , 2011, 76, 711-718.	1.5	154
109	Risk of Development of Medication Overuse Headache With Nonsteroidal Anti-inflammatory Drug Therapy for Migraine. <i>Neurologist</i> , 2011, 17, 297-299.	0.4	21
110	Almotriptan Malate: Early Treatment in Acute Migraine. <i>Clinical Medicine Reviews in Therapeutics</i> , 0, 4, 41-50.	0.4	0
111	How general practitioners treat migraine patients? evaluation of a headache guideline. <i>Cephalalgia</i> , 2012, 32, 908-915.	1.8	6
112	A proactive approach to migraine in primary care: a pragmatic randomized controlled trial. <i>Cmaj</i> , 2012, 184, E224-E231.	0.9	15
113	Overview of migraine treatment. <i>Pain Management</i> , 2012, 2, 399-414.	0.7	1
114	Triptan use in pediatric migraine: focus on rizatriptan. <i>Future Neurology</i> , 2012, 7, 385-394.	0.9	6
115	Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]. <i>Neurology</i> , 2012, 78, 1346-1353.	1.5	295
116	Low rate of self-awareness and medical recognition of migraine in Germany. <i>Cephalalgia</i> , 2012, 32, 1023-1030.	1.8	17

#	ARTICLE	IF	CITATIONS
117	Primary headache disorders and neuro-ophthalmologic manifestations. <i>Eye and Brain</i> , 2012, 4, 49.	3.8	9
118	Optimizing triptan therapy in clinical practice. <i>Clinical Practice (London, England)</i> , 2012, 9, 329-344.	0.1	1
119	Sumatriptan (rectal route of administration) for acute migraine attacks in adults. <i>The Cochrane Library</i> , 2019, 2019, CD009664.	1.5	41
120	Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. <i>The Cochrane Library</i> , 2019, 2019, CD009663.	1.5	22
121	Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. <i>The Cochrane Library</i> , 2019, 2019, CD009665.	1.5	22
122	Diclofenac with or without an antiemetic for acute migraine headaches in adults. , 2012, , CD008783.		15
123	A Randomized Controlled Trial of a Comprehensive Migraine Intervention Prior to Discharge From an Emergency Department. <i>Academic Emergency Medicine</i> , 2012, 19, 1151-1157.	0.8	11
124	Knowledge about and use of pharmacological and non-pharmacological headache therapies. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 716-722.	1.0	1
125	Acceptance of preventive treatment in migraine patients: Results of a survey. <i>European Journal of General Practice</i> , 2012, 18, 143-148.	0.9	5
126	Comorbidity of migraine in children presenting with epilepsy to a tertiary care center. <i>Neurology</i> , 2012, 79, 468-473.	1.5	42
127	Sumatriptan (oral route of administration) for acute migraine attacks in adults. <i>The Cochrane Library</i> , 2019, 2019, CD008615.	1.5	46
128	One-day behavioral treatment for patients with comorbid depression and migraine: A pilot study. <i>Behaviour Research and Therapy</i> , 2012, 50, 537-543.	1.6	55
130	Psychological Issues in the Evaluation and Treatment of Tension-Type Headache. <i>Current Pain and Headache Reports</i> , 2012, 16, 545-553.	1.3	15
131	Perimenstrual Headache in Adolescence. <i>Current Pain and Headache Reports</i> , 2012, 16, 474-476.	1.3	6
132	Comparison of Expected Outcomes between Patients and Neurologists Using Kano's Methodology in Symptomatic Migraine Treatment. <i>Patient</i> , 2012, 5, 147-162.	1.1	9
133	Hearing voices: does it give your patient a headache? A case of auditory hallucinations as acoustic aura in migraine. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 105.	1.0	8
134	Opioid Use and Dependence Among Persons With Migraine: Results of the AMPP Study. <i>Headache</i> , 2012, 52, 18-36.	1.8	103
135	Factors Associated With Triptan Use in Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2012, 52, 213-223.	1.8	25

#	ARTICLE	IF	CITATIONS
136	Concomitant Use of Triptan, and SSRI or SNRI After the US Food and Drug Administration Alert on Serotonin Syndrome. <i>Headache</i> , 2012, 52, 198-203.	1.8	18
137	The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Practice Guidelines. <i>Headache</i> , 2012, 52, 930-945.	1.8	190
138	Self-medication of regular headache: a community pharmacy-based survey. <i>European Journal of Neurology</i> , 2012, 19, 1093-1099.	1.7	60
139	Use of Dopamine Antagonists in Treatment of Migraine. <i>Current Treatment Options in Neurology</i> , 2012, 14, 27-35.	0.7	66
140	Antimigraine medication use and associated health care costs in employed patients. <i>Journal of Headache and Pain</i> , 2012, 13, 121-127.	2.5	15
141	Brain white matter hyperintensities in migraine: Clinical and radiological correlates. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1040-1043.	0.6	34
142	Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. <i>The Cochrane Library</i> , 2019, 2019, CD008040.	1.5	58
143	Sumatriptan/Naproxen Sodium: A Review of Its Use in Adult Patients with Migraine. <i>Drugs</i> , 2013, 73, 1339-1355.	4.9	11
145	Naproxen with or without an antiemetic for acute migraine headaches in adults. <i>The Cochrane Library</i> , 2013, , CD009455.	1.5	28
146	Opioids can be useful in the treatment of headache. <i>Neurological Sciences</i> , 2013, 34, 119-124.	0.9	9
147	Sex Differences in the Prevalence, Symptoms, and Associated Features of Migraine, Probable Migraine and Other Severe Headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2013, 53, 1278-1299.	1.8	330
148	Preventive treatment for migraine in primary care, a population-based study in the Netherlands. <i>Cephalalgia</i> , 2013, 33, 1170-1178.	1.8	20
149	Headache-related health resource utilisation in chronic and episodic migraine across six countries. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1309-1317.	0.9	36
150	Barriers to the Diagnosis and Treatment of Migraine: Effects of Sex, Income, and Headache Features. <i>Headache</i> , 2013, 53, 81-92.	1.8	144
151	Lagniappe: The Impact of Headache Disorders in America*. <i>Headache</i> , 2013, 53, 196-204.	1.8	2
152	Frequency and Burden of Headache-Related Nausea: Results From the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2013, 53, 93-103.	1.8	59
153	Preventive Pharmacologic Treatments for Episodic Migraine in Adults. <i>Journal of General Internal Medicine</i> , 2013, 28, 1225-1237.	1.3	76
154	The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the United States: A Review of Statistics From National Surveillance Studies. <i>Headache</i> , 2013, 53, 427-436.	1.8	319

#	ARTICLE	IF	CITATIONS
155	Management of secondary chronic headache in the general population: the Akershus study of chronic headache. <i>Journal of Headache and Pain</i> , 2013, 14, 5.	2.5	42
156	Prevalence of Migraine and Raynaud Phenomenon in Women With Apical Ballooning Syndrome (Takotsubo or Stress Cardiomyopathy). <i>American Journal of Cardiology</i> , 2013, 111, 1284-1288.	0.7	36
157	Diclofenac with or without an antiemetic for acute migraine headaches in adults. <i>The Cochrane Library</i> , 2019, 2019, CD008783.	1.5	28
158	Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. <i>Journal of Medical Economics</i> , 2013, 16, 490-499.	1.0	13
159	Psychological evaluation of a primary headache patient. <i>Pain Management</i> , 2013, 3, 19-25.	0.7	6
160	Episodic Migraines in Children. <i>Journal of Child Neurology</i> , 2013, 28, 1320-1341.	0.7	7
161	Sumatriptan plus naproxen for acute migraine attacks in adults. , 2013, , CD008541.		14
162	Ibuprofen with or without an antiemetic for acute migraine headaches in adults. <i>The Cochrane Library</i> , 2019, 2019, CD008039.	1.5	81
163	The Experience of Headaches in Health Care Workers: Opportunity for Care Improvement. <i>Headache</i> , 2013, 53, 962-969.	1.8	10
164	Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (<sc>IBMS</sc>). <i>Headache</i> , 2013, 53, 644-655.	1.8	295
165	Childhood and Adolescent Migraine Prevention (<sc>CHAMP</sc>) Study: A Double-Blinded, Placebo-Controlled, Comparative Effectiveness Study of Amitriptyline, Topiramate, and Placebo in the Prevention of Childhood and Adolescent Migraine. <i>Headache</i> , 2013, 53, 799-816.	1.8	73
166	A Cross-Sectional Survey to Assess the Migraineur's Medication Decision-Making Beliefs: Determining When a Migraine Is Triptan-Worthy. <i>Headache</i> , 2013, 53, 1134-1146.	1.8	8
167	Aspirin with or without an antiemetic for acute migraine headaches in adults. <i>The Cochrane Library</i> , 2019, 2019, CD008041.	1.5	44
168	Revised French guidelines for the diagnosis and management of migraine in adults and children. <i>Journal of Headache and Pain</i> , 2014, 15, 2.	2.5	60
169	Migraine and Epilepsy in the Pediatric Population. <i>Current Pain and Headache Reports</i> , 2014, 18, 402.	1.3	29
170	A Pattern Approach to Focal White Matter Hyperintensities on Magnetic Resonance Imaging. <i>Radiologic Clinics of North America</i> , 2014, 52, 241-261.	0.9	18
171	Job stress is associated with migraine in current workers: The <sc>Brazilian Longitudinal Study of Adult Health (ELSA-Brazil)</sc>. <i>European Journal of Pain</i> , 2014, 18, 1290-1297.	1.4	32
172	Targeting TRP Channels For Novel Migraine Therapeutics. <i>ACS Chemical Neuroscience</i> , 2014, 5, 1085-1096.	1.7	77

#	ARTICLE	IF	CITATIONS
173	Headacheâ€attributed burden and its impact on productivity and quality of life in <scp>R</scp>ussia: structured healthcare for headache is urgently needed. European Journal of Neurology, 2014, 21, 758-765.	1.7	59
174	Oneâ€Day Behavioral Intervention in Depressed Migraine Patients: Effects on Headache. Headache, 2014, 54, 528-538.	1.8	43
175	COX inhibitors for the treatment of migraine. Expert Opinion on Pharmacotherapy, 2014, 15, 1863-1874.	0.9	24
176	Preventive Drugs in Childhood and Adolescent Migraine. Current Pain and Headache Reports, 2014, 18, 422.	1.3	34
177	Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. The Cochrane Library, 2019, 2019, CD009108.	1.5	64
178	Meditation-Based Treatment Yielding Immediate Relief for Meditation-NaÃve Migraineurs. Pain Management Nursing, 2014, 15, 36-40.	0.4	35
179	Zolmitriptan for acute migraine attacks in adults. The Cochrane Library, 2014, , CD008616.	1.5	22
180	Headache in African Americans: An Overlooked Disparity. Journal of the National Medical Association, 2015, 107, 39-45.	0.6	5
181	Persistent Frequent Nausea Is Associated With Progression to Chronic Migraine: <scp>AMPP</scp> Study Results. Headache, 2015, 55, 76-87.	1.8	46
182	Proof-of-Principle, Open-Label Prospective Cohort Trial of a Novel Nutraceutical for the Prevention of Refractory Migraine. Journal of Clinical Trials, 2015, 05, .	0.1	0
183	Acute and Preventative Treatment of Episodic Migraine. , 2015, , 69-97.		1
184	Migraine-Related Healthcare Resource Use and Costs for Subjects Prescribed Fixed-Dose Combination Sumatriptan/Naproxen Sodium vs. Single-Entity Oral Triptans in a Managed Care Population in the USA. Applied Health Economics and Health Policy, 2015, 13, 109-120.	1.0	3
185	The Prevalence and Burden of Migraine and Severe Headache in the <scp>U</scp>nited <scp>S</scp>tates: Updated Statistics From Government Health Surveillance Studies. Headache, 2015, 55, 21-34.	1.8	405
186	Prophylaxis of Migraine in Children and Adolescents. Paediatric Drugs, 2015, 17, 217-226.	1.3	24
187	Patent foramen ovale: Unanswered questions. European Journal of Internal Medicine, 2015, 26, 743-751.	1.0	38
188	Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine Pathology. Frontiers in Immunology, 2016, 7, 140.	2.2	21
189	Higher augmentation index is associated with tensionâ€type headache and migraine in middleâ€aged/older humans with obesity. Obesity, 2016, 24, 865-870.	1.5	7
190	Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. The Cochrane Library, 2016, 4, CD008541.	1.5	29

#	ARTICLE	IF	CITATIONS
191	Recent advances in migraine therapy. SpringerPlus, 2016, 5, 637.	1.2	103
192	Development and Validation of a Four-Item Migraine Screening Algorithm Among a Nonclinical Sample: The Migraine-4. Headache, 2016, 56, 86-94.	1.8	14
194	Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). Cephalalgia, 2016, 36, 203-215.	1.8	42
195	Blood gene expression studies in migraine: Potential and caveats. Cephalalgia, 2016, 36, 669-678.	1.8	19
196	Migraine diagnosis and treatment: A knowledge and needs assessment among primary care providers. Cephalalgia, 2016, 36, 358-370.	1.8	45
197	Clinical impact of migraine for the management of glaucoma patients. Progress in Retinal and Eye Research, 2016, 51, 107-124.	7.3	14
198	The quality of diagnosis and management of migraine and tension-type headache in three social groups in Russia. Cephalalgia, 2017, 37, 225-235.	1.8	13
199	Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN02. Journal of Clinical Pharmacology, 2017, 57, 1472-1478.	1.0	3
201	A critical review of manual therapy use for headache disorders: prevalence, profiles, motivations, communication and self-reported effectiveness. BMC Neurology, 2017, 17, 61.	0.8	46
202	Primary Headaches in an Elderly Population Seeking Medical Care for Cognitive Decline. Headache, 2017, 57, 209-216.	1.8	15
203	A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns. Headache, 2017, 57, 1532-1544.	1.8	86
204	Pediatric Headache and Seizures. Seminars in Pediatric Neurology, 2017, 24, 310-319.	1.0	5
205	Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study. Headache, 2017, 57, 1026-1040.	1.8	49
206	Preventing Episodic Migraine With Caloric Vestibular Stimulation: A Randomized Controlled Trial. Headache, 2017, 57, 1065-1087.	1.8	42
207	Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study. Cephalalgia, 2017, 37, 955-964.	1.8	22
208	Prescription Patterns and the Cost of Migraine Treatments in German General and Neurological Practices. Pain Practice, 2017, 17, 747-752.	0.9	8
209	Ergotamine Use and Overuse in Taiwan: A Retrospective Cohort Study. Headache, 2018, 58, 416-423.	1.8	3
210	One-Day Behavioral Intervention for Distressed Veterans with Migraine: Results of a Multimethod Pilot Study. Military Medicine, 2018, 183, e184-e192.	0.4	9

#	ARTICLE	IF	CITATIONS
211	Differences in Pediatric Headache Prescription Patterns by Diagnosis. <i>Paediatric Drugs</i> , 2018, 20, 273-284.	1.3	7
212	Migraine-preventive prescription patterns by physician specialty in ambulatory care settings in the United States. <i>Preventive Medicine Reports</i> , 2018, 9, 62-67.	0.8	13
213	Perceived triggers of primary headache disorders: A meta-analysis. <i>Cephalalgia</i> , 2018, 38, 1188-1198.	1.8	152
214	Impact of migraine on health care utilization and expenses in obese adults: a US population-based study. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 51-59.	0.7	1
215	The validation of the Hungarian version of the ID-migraine questionnaire. <i>Journal of Headache and Pain</i> , 2018, 19, 106.	2.5	9
216	A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. <i>BMC Neurology</i> , 2018, 18, 188.	0.8	114
217	Bidirectional relations among common psychiatric and neurologic comorbidities and epilepsy: Do they have an impact on the course of the seizure disorder?. <i>Epilepsia Open</i> , 2018, 3, 210-219.	1.3	41
219	A Critical Exploration of Migraine as a Health Disparity: the Imperative of an Equity-Oriented, Intersectional Approach. <i>Current Pain and Headache Reports</i> , 2018, 22, 79.	1.3	33
220	Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1785-1795.	0.8	22
221	The effect of gender disparity on migraine pharmacotherapy: a propensity score-matched cohort study. <i>Journal of Pharmaceutical Health Services Research</i> , 2018, 9, 191-197.	0.3	0
222	Evaluation of Galcanezumab for the Prevention of Episodic Migraine. <i>JAMA Neurology</i> , 2018, 75, 1080.	4.5	413
223	Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. <i>Cephalalgia</i> , 2018, 38, 1442-1454.	1.8	384
224	Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine. <i>Medical Devices: Evidence and Research</i> , 2018, Volume 11, 147-156.	0.4	12
225	A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience. <i>Acta Neurologica Belgica</i> , 2018, 118, 475-484.	0.5	7
226	Headache, Facial Pain, and Disorders of Facial Sensation. , 2019, , 661-684.		1
227	Prevalence and factors associated with the use of primary headache diagnostic criteria by chiropractors. <i>Chiropractic & Manual Therapies</i> , 2019, 27, 33.	0.6	6
228	Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. <i>Journal of Headache and Pain</i> , 2019, 20, 84.	2.5	36
229	Preventive Treatment for Episodic Migraine. <i>Neurologic Clinics</i> , 2019, 37, 753-770.	0.8	29

#	ARTICLE	IF	CITATIONS
230	Nonpharmacological Self-Management of Migraine Across Social Locations: An Equity-Oriented, Qualitative Analysis. <i>Global Advances in Health and Medicine</i> , 2019, 8, 216495611985803.	0.7	7
231	Antidepressants for Preventive Treatment of Migraine. <i>Current Treatment Options in Neurology</i> , 2019, 21, 18.	0.7	60
232	Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. <i>Cephalalgia</i> , 2019, 39, 1086-1098.	1.8	25
233	Assessing evidence-based medicine and opioid/barbiturate as first-line acute treatment of pediatric migraine and primary headache: A retrospective observational study of health systems data. <i>Cephalalgia</i> , 2019, 39, 1000-1009.	1.8	7
234	Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care. <i>Journal of Headache and Pain</i> , 2019, 20, 13.	2.5	29
235	European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. <i>Journal of Headache and Pain</i> , 2019, 20, 6.	2.5	260
236	Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions. <i>Value in Health</i> , 2019, 22, 293-302.	0.1	4
237	Migraine and Tension-Type Headache. <i>Medical Clinics of North America</i> , 2019, 103, 215-233.	1.1	75
238	Self-Medication With Over-the-Counter Analgesics: A Survey of Patient Characteristics and Concerns About Pain Medication. <i>Journal of Pain</i> , 2019, 20, 215-223.	0.7	25
239	Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database. <i>Current Medical Research and Opinion</i> , 2020, 36, 51-61.	0.9	6
240	Physical therapist clinical reasoning and classification inconsistencies in headache disorders: a United States survey. <i>Journal of Manual and Manipulative Therapy</i> , 2020, 28, 28-40.	0.7	7
241	The Role of Magnesium in Pathophysiology and Migraine Treatment. <i>Biological Trace Element Research</i> , 2020, 196, 375-383.	1.9	46
242	Migraine Awareness in Italy and the Myth of "Cervical Arthrosis". <i>Headache</i> , 2020, 60, 81-89.	1.8	13
243	Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. <i>European Journal of Neurology</i> , 2020, 27, 536-541.	1.7	47
244	Randomized Clinical Trials of PFO Closure for Migraine Headache (MIST, PRIMA, PREMIUM). , 2020, , 129-139.		0
245	Translation and validation of an extended German version of ID Migraine as a migraine screening tool. <i>Cephalalgia Reports</i> , 2020, 3, 251581632096277.	0.2	5
246	An Evidence-Based Review of Galcanezumab for the Treatment of Migraine. <i>Neurology and Therapy</i> , 2020, 9, 403-417.	1.4	3
247	Smartphone-Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial. <i>Headache</i> , 2020, 60, 2232-2246.	1.8	30

#	ARTICLE	IF	CITATIONS
248	Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study. <i>Journal of Headache and Pain</i> , 2020, 21, 109.	2.5	12
249	Use of outpatient medical care by headache patients in Germany: a population-based cross-sectional study. <i>Journal of Headache and Pain</i> , 2020, 21, 49.	2.5	9
250	Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. <i>Journal of Headache and Pain</i> , 2020, 21, 53.	2.5	20
251	A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment. <i>Headache</i> , 2020, 60, 1325-1339.	1.8	14
252	Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis. <i>Journal of Headache and Pain</i> , 2020, 21, 85.	2.5	14
253	Characteristics of migraine patients with Migraine Disability Assessment (MIDAS) scores in real-world clinical practice. <i>Cephalalgia Reports</i> , 2020, 3, 251581632092846.	0.2	4
254	Do doctors treat themselves differently than their patients? Study on the self-treatment of migraine among German neurologists and pain specialists. <i>Cephalalgia</i> , 2020, 40, 788-796.	1.8	4
255	A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 537-543.	1.0	0
256	How Does Migraine Change After 10 Years? A Clinical Cohort Follow-up Analysis. <i>Headache</i> , 2020, 60, 916-928.	1.8	3
257	Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review. <i>Pharmacoeconomics</i> , 2020, 38, 473-484.	1.7	5
258	Burden of migraine in Finland: multimorbidity and phenotypic disease networks in occupational healthcare. <i>Journal of Headache and Pain</i> , 2020, 21, 8.	2.5	12
259	Multimodal chiropractic care for migraine: A pilot randomized controlled trial. <i>Cephalalgia</i> , 2021, 41, 318-328.	1.8	2
260	Pooled Analysis of PFO Occluder Device Trials in Patients With PFO and Migraine. <i>Journal of the American College of Cardiology</i> , 2021, 77, 667-676.	1.2	46
261	A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 467-474.	1.0	7
262	Treatment of migraine: a review of disease burden and an update on the therapeutic landscape for pharmacists. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 75-86.	0.3	3
263	Medicines for headache before and during pregnancy: a retrospective cohort study (ATENA study). <i>Neurological Sciences</i> , 2021, 42, 1895-1921.	0.9	3
264	Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study. <i>Current Medical Research and Opinion</i> , 2021, 37, 443-457.	0.9	1
265	Evaluation of the Item Identify Chronic Migraine screener in a large medical group. <i>Headache</i> , 2021, 61, 335-342.	1.8	5

#	ARTICLE	IF	CITATIONS
266	Perceptions of Chiropractic Care Among Women With Migraine: A Qualitative Substudy Using a Grounded-Theory Framework. <i>Journal of Manipulative and Physiological Therapeutics</i> , 2021, 44, 154-163.	0.4	5
267	Galcanezumab for the prevention of migraine. <i>Pain Management</i> , 2021, 11, 101-112.	0.7	4
268	The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions. <i>Pharmaceuticals</i> , 2021, 14, 245.	1.7	2
269	Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study. <i>Headache</i> , 2021, 61, 628-641.	1.8	35
270	Naturalistic assessment of patterns and predictors of acute headache medication use among women with comorbid migraine and overweight or obesity. <i>Translational Behavioral Medicine</i> , 2021, 11, 1495-1506.	1.2	0
271	The efficacy of botulinum toxin type-A for intractable chronic migraine patients with no pain-free time. <i>British Journal of Pain</i> , 2022, 16, 41-49.	0.7	4
272	Treatment Realities of Headache Disorders in Rural Germany by the Example of the Region of Western Pomerania. <i>Brain Sciences</i> , 2021, 11, 839.	1.1	3
273	Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor. <i>Neurology and Therapy</i> , 2021, 10, 469-497.	1.4	9
274	Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. <i>Journal of Headache and Pain</i> , 2021, 22, 81.	2.5	11
275	Optimal management strategies for primary headache in the emergency department. <i>Canadian Journal of Emergency Medicine</i> , 2021, 23, 802-811.	0.5	3
276	Fremanezumab autoinjector pen for the prevention of migraine. <i>Therapeutic Delivery</i> , 2021, 12, 645-650.	1.2	1
277	Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1157-1170.	0.5	4
279	Eletriptan for acute migraine headaches in adults. , 2010, 2010, .		2
280	Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1ÂYear of Treatment in the PROMISE-1 Study. <i>Clinical Therapeutics</i> , 2020, 42, 2254-2265.e3.	1.1	35
281	Contributions of Epidemiology to Our Understanding of Migraine. <i>Headache</i> , 2013, 53, 230-246.	1.8	152
282	The migraine signature study: Methods and baseline results. <i>Headache</i> , 2021, 61, 462-484.	1.8	7
283	Vascular safety of erenumab for migraine prevention. <i>Neurology</i> , 2020, 94, e497-e510.	1.5	66
284	CGRP monoclonal antibodies for migraine prophylaxis. <i>Neurologie Pro Praxi</i> , 2019, 20, 356-360.	0.0	2

#	ARTICLE	IF	CITATIONS
285	Comparison of Treatment Effect of Sodium Valproate, Propranolol and Tricyclic Antidepressants in Migraine. Pakistan Journal of Biological Sciences, 2009, 12, 1098-1101.	0.2	5
286	A central analgesic mechanism of acupuncture for migraine: An ongoing functional MRI study. Neural Regeneration Research, 2013, 8, 2649-55.	1.6	6
287	The need for preventive therapy in primary headaches. Headache Medicine, 2011, 2, 46-49.	0.1	4
288	The role of magnesium in migraine pathogenesis. Potential use of magnesium compounds in prevention and treatment of migraine headaches. Journal of Elementology, 2012, , .	0.0	6
290	Headache, facial pain, and disorders of facial sensation. , 2010, , 661-684.		1
293	General Issues Arising from the Use of Drugs for Headache Disorders. , 2011, , 611-617.		0
295	Pain in infancy and childhood. , 2012, , 316-331.		0
297	Comparison of Expected Outcomes between Patients and Neurologists Using Kano's Methodology in Symptomatic Migraine Treatment. Patient, 2012, 5, 147-162.	1.1	7
298	Headache in children. , 2013, , 1004-1009.		0
302	The Association of Patent Foramen Ovale and Migraine Headache. , 2015, , 81-94.		0
303	Headache in pregnancy. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2017, 117, 136.	0.1	0
305	Pandemonium Versus Paralysis: The Internal Experience of Adolescent Girls with Headaches. American Journal of Qualitative Research, 2020, 4, 49-68.	0.3	0
306	Automatic migraine classification using artificial neural networks. F1000Research, 2020, 9, 618.	0.8	1
307	Douleur aiguë ou chronique : des syndromes particuliers, une prise en charge adaptée. Douleurs, 2021, 22, S1-S10.	0.0	0
308	Effects of treatment of temporomandibular disorders on headache, quality of life, and neck function in patients with tension-type headaches: a randomized controlled study. Physical Therapy Rehabilitation Science, 2020, 9, 215-221.	0.1	1
309	Pathophysiology and Diagnosis of Nerve Compression Headache. , 2020, , 1-13.		0
310	Automatic migraine classification using artificial neural networks. F1000Research, 0, 9, 618.	0.8	10
311	The pharmacological management of migraine, part 2: preventative therapy. P and T, 2008, 33, 480-7.	1.0	5

#	ARTICLE	IF	CITATIONS
312	The pharmacological management of migraine, part 1: overview and abortive therapy. P and T, 2008, 33, 404-16.	1.0	8
314	Comparison of Intravenous Metoclopramide and Acetaminophen in Primary Headaches: a Randomized Controlled Trial. Emergency, 2015, 3, 70-4.	0.6	6
315	The management and clinical knowledge of headache disorders among general practitioners in Norway: a questionnaire survey. Journal of Headache and Pain, 2021, 22, 136.	2.5	2
316	Bidirectional Relations Among Depression, Migraine, and Epilepsy: Do They Have an Impact on Their Response to Treatment?. Current Topics in Behavioral Neurosciences, 2021, , 1.	0.8	0
318	Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. Headache, 2022, 62, 122-140.	1.8	43
319	Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis. Journal of Interventional Cardiology, 2022, 2022, 1-7.	0.5	7
320	Cognitive or daily stress association with headache and pain induction in migraine and tension-type headache patients: a systematic review. Expert Review of Neurotherapeutics, 2022, 22, 257-268.	1.4	5
321	Preventive and Therapeutic Aspects of Migraine for Patient Care: An Insight. Current Molecular Pharmacology, 2023, 16, 147-160.	0.7	1
322	Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 814-823.	0.7	7
323	Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(̂~receptor) antibodies. Journal of Headache and Pain, 2021, 22, 158.	2.5	13
324	Combining patient reported outcomes and EHR data to understand population level treatment needs: correcting for selection bias in the migraine signature study. Journal of Patient-Reported Outcomes, 2021, 5, 132.	0.9	3
326	A Comprehensive Review of Celecoxib Oral Solution for the Acute Treatment of Migraine. Health Psychology Research, 2022, 10, .	0.6	0
327	Development and validation of a web-based headache diagnosis questionnaire. Scientific Reports, 2022, 12, 7032.	1.6	9
328	Treatment of migraine with monoclonal antibodies. Expert Opinion on Biological Therapy, 2022, 22, 707-716.	1.4	3
329	Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study. Headache, 2022, 62, 755-765.	1.8	5
330	Evaluation and treatment of acute migraine in the emergency department. Pamukkale Medical Journal, 0, , .	0.2	0
331	Managing migraine on the frontline: Identifying disease, understanding burden, and incorporating CGRP pathway-targeting therapies in primary care. British Journal of Pain, 2022, 16, 560-573.	0.7	1
332	Headache, eating disorders, PTSD, and comorbidity: implications for assessment and treatment. Eating and Weight Disorders, 0, , .	1.2	2

#	ARTICLE	IF	CITATIONS
333	A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine. Health Psychology Research, 2022, 10, .	0.6	3
334	Migraine, Migraine Disability, Trauma, and Discrimination in Sexual and Gender Minority Individuals. Neurology, 0, , 10.1212/WNL.0000000000200941.	1.5	7
336	Preventive Treatment of Migraine. Seminars in Neurology, 0, , .	0.5	0
337	Migraine in physicians and final year medical students: A cross-sectional insight into prevalence, self-awareness, and knowledge from Pakistan. World Journal of Methodology, 2022, 12, 414-427.	1.1	3
338	A non-oral gepant for acute treatment of migraine. Headache, 2022, 62, 1075-1076.	1.8	0
339	Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I. Arquivos De Neuro-Psiquiatria, 2022, 80, 845-861.	0.3	3
340	Rimegepant for the treatment of migraine. Health Psychology Research, 2022, 10, .	0.6	4
341	Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Clinical Neurology and Neurosurgery, 2022, 223, 107511.	0.6	1
342	Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults. Health Psychology Research, 2022, 10, .	0.6	0
343	Predictors of treatment-response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti-inflammatory drugs in acute treatment of episodic migraine. Headache, 2023, 63, 342-352.	1.8	2
345	Dietary supplementation in migraine: A focus on omega-3 fatty acids. , 2023, , 381-400.		0
352	Evidence-based preventive treatment of migraine. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 219-241.	1.0	0